• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Eli Lilly (LLY) Fully Priced On Its Q3 Beat And Raised Outlook?

    Simply Wall St·10/31/2026 23:34:31
    Listen to the news

    Eli Lilly (LLY) just cleared a high bar. Third quarter sales and profit topped analyst forecasts, powered by strong demand for Mounjaro and Zepbound, and management lifted its full year revenue outlook.

    The upbeat guidance and clinical wins are reflected in the trading data. Eli Lilly’s 1-month share price return of 22.5% and 90-day gain of 23.4% signal building momentum, while a 1-year total shareholder return of 65.3% caps an already strong multi-year run.

    Scan Eli Lilly’s peers riding similar GLP-1 and healthcare tailwinds by focusing on our hand-picked 34 healthcare AI stocks for your next round of research.

    Bulls see Eli Lilly’s Q3 beat and raised US$91b to US$92b revenue outlook as proof the premium is earned. Bears see a crowded GLP-1 field and patent clocks ticking. Which story does the current valuation reflect?

    Most Popular Narrative: 4% Undervalued

    According to AHaron's widely followed narrative, Eli Lilly's fair value of $1,477.03 sits modestly above the last close at $1,417.54, which points to a mild undervaluation built on specific growth and pipeline assumptions rather than broad market optimism.

    The model uses four inputs to arrive at the fair value: a growth rate that has been adjusted to 18% to reflect reality rather than the overly conservative 12.71% default; a future PE ratio of 30 times earnings in 2031, down from today's 39 times, which accounts for the natural compression in valuation multiples as a company matures and grows larger; a discount rate of 7.5%, slightly above the default of 6.98%, to account for the pipeline risks that still exist; and earnings by 2031 of approximately $48 to $50 billion, above the model's $41.5 billion, based on an 18% growth rate and stable margins.

    See why 80 investors see Eli Lilly as 4% undervalued.

    Result: Fair Value of $1,477.03 (UNDERVALUED)

    Still, Eli Lilly’s story can change quickly if GLP-1 pricing pressure intensifies or if key late stage trials fail to match current expectations.

    Find out about the key risks to this Eli Lilly narrative.

    Next Steps

    Plenty of investors see Eli Lilly as slightly cheap, while others focus on the risks that could swing sentiment fast. Move quickly and test the data for yourself, then weigh both sides through our 3 key rewards and 2 important warning signs

    Looking for more ideas beyond Eli Lilly?

    If Eli Lilly sharpened your focus on quality, do not stop there. Consider broadening your watchlist with a few targeted sets of opportunities built from hard data.